Because you help to protect him from another life-changing CV event1,2
Approved in the EU since 20153
Repatha® is a groundbreaking medicine first approved in 2015 for the reduction of LDL-C as an adjunct to statins3 and approved in 2018 for reduction of cardiovascular risk in people with a history of heart attack, stroke or peripheral artery disease.4
PCSK9 inhibitors endorsed in 2019 ESC/EAS Dyslipidaemia Guidelines5
The 2019 update of the ESC/EAS dyslipidaemia guidelines support a “lower is better” approach through more intensive reduction of LDL-C across CV risk categories.5
PCSK9 inhibitors like Repatha® are endorsed as the standard of care with the highest level of recommendation (I A) for very-high-risk secondary prevention patients who have not achieved their LDL-C goals on maximum tolarated statin and ezetimibe therapy.5Discover the 2019 dyslipidaemia guidelines
*In the study, 2690 recent MI patients received Repatha®, 2254 of whom achieved LDL-C levels <55 mg/dl. †25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62-0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2-5.2.
ACS = Acute coronary syndrome; ARR = Absolute risk reduction; CV = Cardiovascular; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; EU = European Union; EVOPACS = EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes; LDL-C = Low-density lipoprotein cholesterol; MI = Myocardial infarction; PCSK9 = Protein convertase subtilisin/kexin type 9; RRR = Relative risk reduction.